Search | Clinical Trials Finder

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: WST-057 Active, Placebo; Drug
Lead sponsor: WinSanTor, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Neuralgia, Postherpetic Neuralgia, Reflex Sympathetic Dystrophy, Complex Regional Pain Syndrome (CRPS)
Interventions: Pennsaid, Placebo (2.3% DMSO solution); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sturge Weber Syndrome, Port-wine Mark
Interventions: Timolol, Preservative free artificial tear gel.; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 2 Years to 10 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Healthy Volunteers
Interventions: Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Atopic Dermatitis
Interventions: Tezepelumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Artesia, California • Los Angeles, California • Torrance, California + 9 more

Conditions: Pain, Acute Otitis Media
Interventions: Benzocaine, Placebo; Drug
Lead sponsor: Otic Therapy, LLC; Industry
Eligibility: 2 Months to 12 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Clearwater, Florida • Gresham, Oregon • Murray, Utah

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Acute Oral Mucositis Pain
Interventions: doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 350
States / cities: Anchorage, Alaska • Burbank, California • Dublin, California + 221 more

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions: 5-fluorouracil, Placebo, vehicle control; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Infantile Nystagmus Syndrome
Interventions: topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser; Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Dry Eye Syndromes
Interventions: Cyclosporine A, Placebo; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more

Conditions: Head and Neck Carcinoma, Radiation-Induced Dermatitis
Interventions: Dakin's solution, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions: SURF-201, Placebo; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Hemet, California • Murrieta, California • Brooksville, Florida + 7 more

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, Placebo; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: San Diego, California • College Station, Texas

Conditions: Fluid Retention, Fluid Loss, Sodium Retention, Cognitive Change, Heat Exposure, Hyperhydration, Electrolyte and Fluid Balance Conditions
Interventions: PR Lotion - AMP Human Performance, Placebo Lotion; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Onychomycosis
Interventions: terbinafine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 20
States / cities: Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more

Conditions: Glutathione-cyclodextrin Complex Absorption
Interventions: Glutaryl Solution, Placebo Solution; Dietary Supplement
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Pomona, California

Conditions: Diabetic Retinopathy
Interventions: Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements; Drug · Other
Lead sponsor: Stephen J. Kim, MD; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions: Dorzolamide-timolol, Artificial tears; Drug · Other
Lead sponsor: Wills Eye; Other
Eligibility: 45 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more

Conditions: Epiphora, Dacryostenosis, Dacryocystitis
Interventions: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Interventions: Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution; Drug
Lead sponsor: Lannett Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy

Effects of Pennsaid on Clinical Neuropathic Pain

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycobacterium Infection

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia